ChromaDex (NASDAQ:CDXC) Downgraded to Buy Rating by StockNews.com

StockNews.com cut shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a report issued on Friday morning.

A number of other research analysts also recently issued reports on CDXC. Roth Mkm boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright boosted their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th.

ChromaDex Trading Up 0.5 %

Shares of NASDAQ:CDXC opened at $5.51 on Friday. The stock has a 50 day moving average of $6.29 and a 200 day moving average of $4.24. The company has a market cap of $420.87 million, a PE ratio of 551.55 and a beta of 2.15. ChromaDex has a 12-month low of $1.36 and a 12-month high of $7.97.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the previous year, the company posted ($0.01) EPS. Equities research analysts predict that ChromaDex will post 0.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.64% of the stock is owned by insiders.

Institutional Trading of ChromaDex

Several hedge funds have recently modified their holdings of CDXC. Bank of New York Mellon Corp raised its holdings in shares of ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock worth $520,000 after acquiring an additional 119,915 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of ChromaDex during the 2nd quarter worth approximately $124,000. WINTON GROUP Ltd purchased a new stake in shares of ChromaDex during the 2nd quarter worth approximately $597,000. Dimensional Fund Advisors LP purchased a new stake in shares of ChromaDex during the 2nd quarter worth approximately $88,000. Finally, Renaissance Technologies LLC raised its holdings in ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after buying an additional 32,400 shares during the period. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.